Global Tuberculosis Report 2026 web banner

4.2 International donor funding for tuberculosis

An analysis of donor reports to the Organisation for Economic Co-operation and Development

In 2002, the World Health Organization (WHO) started annual monitoring of funding for tuberculosis (TB) prevention, diagnostic and treatment services, based on data reported by national TB programmes (NTPs) in annual rounds of global TB data collection. Findings have been published in global TB reports and peer-reviewed publications (1–3). However, not all international donor funding for TB is captured in the data reported to WHO. Therefore, each year, WHO complements its analysis of data reported by NTPs with an assessment of international donor funding for TB, based on donor reports to the Organisation for Economic Co-operation and Development (OECD).

The OECD’s creditor reporting system (CRS) (4) is the most comprehensive source of information about international donor funding. The CRS Aid Activity database makes it possible to analyse where aid goes, what purposes it serves and what policies it aims to support, on a comparable basis for all members of the OECD Development Assistance Committee (DAC). Data are for countries or areas eligible to receive official development assistance (ODA); currently, this group comprises 141 countries and areas, of which 128 are low and middle-income countries (LMICs). Data are collected for individual projects and programmes, with a focus on financial data (4).

As of 2026, funding data (both commitments and disbursements) were provided by 36 multilateral donor organizations, 34 members of the OECD’s DAC (33 individual countries and the European Union) and a further 18 countries beyond the DAC that report to the OECD. Disbursement data include both direct transfers to countries and the provision of goods and services (e.g. in-kind transfers or technical assistance). Of note, the CRS does not capture funding for TB that flows from one OECD member to an institution or government within the OECD. In addition, government contributions that are channelled through multilateral organizations — such as The Global Fund — are attributed to the multilateral organization and not to the government of origin.

As of July 2026, the latest year for which data had been reported was 2024; data on gross total official disbursements for TB (code 12263: Tuberculosis control) received by non-OECD countries during 2013–2024 were analysed. Importantly, this means that a major limitation of the currently available dataset is that it does not yet capture recent and substantial changes to the landscape of international donor funding. These have been most obvious in 2025, but a reduction in funding (following 5 years of continuous growth) was already evident in 2024 (5).

Fig. 4.2.1 shows trends in international donor funding for the TB response in the 141 countries and areas eligible to receive ODA (as defined by the OECD) between 2013 and 2024, both overall and for each WHO region. In this period, total funding from all sources ranged from about US$ 1.0 billion to US$ 1.3 billion per year. There was a reduction of 17% between 2022 (US$ 1.3 billion) and 2024 (US$ 1.1 billion).

Throughout the period 2013–2024, The Global Fund was consistently the largest provider of international donor funding for TB in LMICs, accounting for 63% on average. In 2024, funding from the Global Fund amounted to US$ 675 million (62% of the global total of US$ 1.1 billion).

Fig. 4.2.1 International donor funding for TB by source based on donor reports to the OECD, for 141 countries and areas eligible to receive ODA, overall and by WHO region,a 2013–2024

OECD: Organisation for Economic Co-operation and Development.
a The OECD defines 141 countries and areas as eligible for ODA, of which 128 are LMICs. The subtotals for the six WHO regions do not sum to the total for all LMICs combined. This is because funding recorded in regional (rather than country-specific) categories used by the OECD cannot be matched to a specific WHO region, and the recipient country for country-level funding is sometimes not specified.

Annual disbursements of bilateral funding from the United States of America (US) between 2013 and 2024 that were recorded in the OECD database (Fig. 4.2.1) ranged from US$ 223 million to US$ 314 million. In 2024, the total amount disbursed was US$ 326 million; the largest share (30%) was provided to countries in the WHO African Region. These amounts were lower than official US congressional allocations for TB (6, 7), which grew from US$ 232 million in 2013 to US$ 406 million in 2023–2025 and slightly declined to US$ 390 million in 2026 (Fig. 4.2.2).

 

Fig. 4.2.2 Official US congressional allocations of funding for TB, 2013–2026


When bilateral funding from individual countries reported to the OECD is combined with estimates of individual country contributions for TB that are channelled through The Global Fund, the US government was by far the largest source of international donor funding for TB, accounting for 49% of the total in the period 2013–2024 (Fig. 4.2.3). In the most recent year for which data are available (2024), the share was 47%.

After the US government, the next largest individual country contributors in the period 2013–2024 were (in order of their contribution) the United Kingdom of Great Britain and Northern Ireland (7.8%), France (6.5%), Germany (5.8%), Canada (4.5%) and Japan (4.4%). Preliminary OECD DAC data indicate that total ODA declined in real terms in 2025 for all five countries (8). Several also reduced their pledges to the Global Fund replenishment 2026–2028 grant cycle (9, 10); this will impact funding for the health sector, including the TB response, from 2026.

Fig. 4.2.3 Distribution of international donor funding for TB when Global Fund contributions are allocated to individual countries and other reporting entities,a 2013–2024

Funding totals for each entity are the sum of a) funding reported to the OECD, excluding that channelled via The Global Fund and b) an estimate of the funding provided for TB via The Global Fund.b

 

Fig. 4.2.3 Distribution of international donor funding for TB when Global Fund contributions are allocated to individual countries and other reporting entities, 2013–2024
OECD: Organisation for Economic Co-operation and Development; United Kingdom: United Kingdom of Great Britain and Northern Ireland.
a Other reporting entities include any countries beyond the 10 that are labelled that provide international donor funding for TB, and multilateral agencies (excluding The Global Fund).
b The estimate is based on the assumption that the share of a country or other entity’s contribution to TB funding provided by The Global Fund is the same as its share of total contributions to The Global Fund. For example, if a country provided 5% of the total contributions to The Global Fund, it was assumed to provide 5% of the TB funding attributed to The Global Fund in the OECD database.


The amount of international funding for TB (US$ 1.1 billion in 2024) is much less than that for malaria (US$ 2.2 billion in 2024) and HIV (US$ 10.4 billion in 2024) (Fig. 4.2.4). Overall, TB funding constitutes 3.6% of total ODA funding for health and population programmes (US$ 30 billion in 2024).

Fig. 4.2.4 International donor funding for health and population programmes, TB, HIV and malaria, 2013–2024

HIV: human immunodeficiency virus; STD: sexually transmitted disease.


References

  1. Floyd K, Fitzpatrick C, Pantoja A, Raviglione M. Domestic and donor financing for tuberculosis care and control in low-income and middle-income countries: an analysis of trends, 2002–11, and requirements to meet 2015 targets. Lancet Glob Health. 2013;1(2):e105–15 (https://doi.org/10.1016/S2214-109X(13)70032-9).

  2. Floyd K, Pantoja A, Dye C. Financing tuberculosis control: the role of a global financial monitoring system. Bull World Health Organ. 2007;85(5):334–40 (https://doi.org/10.2471/blt.06.034942).

  3. Su Y, Garcia Baena I, Harle AC, Crosby SW, Micah AE, Siroka A et al. Tracking total spending on tuberculosis by source and function in 135 low-income and middle-income countries, 2000–17: a financial modelling study. Lancet Infect Dis. 2020;20(8):929–42 (https://doi.org/10.1016/S1473-3099(20)30124-9).

  4. OECD Data Explorer [website]. Paris: Organisation for Economic Co-operation and Development; 2026 (https://data-explorer.oecd.org/).

  5. International aid falls in 2024 for first time in six years, says OECD [website]. Organisation for Economic Co-operation and Development; 2025 (https://www.oecd.org/en/about/news/press-releases/2025/04/official-development-assistance-2024-figures.html).

  6. Breaking Down the U.S. Global Health Budget by Program Area [website]. San Francisco: Kaiser Family Foundation; 2026 (https://www.kff.org/global-health-policy/breaking-down-the-u-s-global-health-budget-by-program-area).

  7. US foreign assistance dashboard [website]. Washington, D.C.: Office of Management and Budget, Agency Congressional Budget Justifications, Congressional Appropriation Bills; 2026 (https://foreignassistance.gov/).

  8. A historic decline in foreign aid: Preliminary 2025 ODA data [website]. Paris: Organisation for Economic Co-operation and Development; 2026 (https://www.oecd.org/en/data/insights/data-explainers/2026/04/a-historic-decline-in-foreign-aid-preliminary-2025-oda-data.html).

  9. Global Fund Board welcomes final eighth replenishment outcome of US$12.64 billion, backs strategic shifts to advance countries’ path to self-reliance [website]. Global Fund to Fight AIDS, Tuberculosis and Malaria; 2026 (https://www.theglobalfund.org/en/news/2026/2026-02-18-global-fund-board-welcomes-final-eighthreplenishment-outcome/).

  10. Global Fund board hails record-breaking seventh replenishment final outcome of US$15.7 billion [website]. Global Fund to Fight AIDS, Tuberculosis and Malaria; 2022 (https://www.theglobalfund.org/en/news/2022/2022-11-18-global-fund-board-hails-record-breaking-seventhreplenishment-final-outcome-of-usd157-billion/).